Lung Diseases Clinical Trial
Official title:
Evaluation of Positive Expiratory Pressure Device (PEP-device) for Treatment of Swimming Induced Pulmonary Edema (SIPE) - a Randomized Single-blinded Controlled Study
In swimming induced pulmonary edema (SIPE), there is a lack of knowledge regarding optimal treatment. The present study was designed to assess the benefit of treatment with positive expiratory pressure device (PEP-device) compared to spontaneous recovery in patients with SIPE without hypoxia in the out-of-hospital environment.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | July 15, 2025 |
Est. primary completion date | July 15, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - clinical diagnosis of swimming induced pulmonary edema (SIPE) with need of acute treatment - peripheral oxygen saturation =92% - 18 years or older - informed consent Exclusion Criteria: - declined consent - suspected acute coronary syndrome - severe asthma diagnosed together with pulmonary edema with requirement of beta-agonist-inhalation prior to treatment of pulmonary edema - hemodynamic instability or decreased consciousness |
Country | Name | City | State |
---|---|---|---|
Sweden | Center of Clinical Research Dalarna | Falun |
Lead Sponsor | Collaborator |
---|---|
Dalarna County Council, Sweden |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Absolute peripheral oxygen saturation (%) after treatment | Peripheral oxygen saturation % (continuous variable) measured by peripheral pulse oximetry | after 20 min treatment followed by 10 min rest | |
Secondary | Change in absolute peripheral oxygen saturation (%) before and after treatment | Change in peripheral oxygen saturation % (continuous variable) measured by pulse oximetry before and after treatment | change before versus after 20 min treatment followed by 10 min rest | |
Secondary | Recovery (yes/no) after treatment | Recovery, defined by "peripheral oxygen saturation >95% after treatment" or no recovery, defined by "peripheral oxygen saturation =95% after treatment" | after 20 min treatment followed by 10 min rest | |
Secondary | Interstitial syndrome assessed by lung ultrasound (yes/no) after treatment | Four chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Bilateral or unilateral presence of two or more positive regions define positive interstitial syndrome | after 20 min treatment followed by 10 min rest | |
Secondary | Absolute number of regions presenting B-lines on lung ultrasound after treatment | Four chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Assessment of the total number of positive regions. | after 20 min treatment followed by 10 min rest | |
Secondary | Change in absolute number of regions presenting B-lines on lung ultrasound before and after treatment | Four chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Assessment of the total number of positive regions. Change in absolute number of regions presenting B-lines on lung ultrasound before and after treatment | change before versus after 20 min treatment followed by 10 min rest | |
Secondary | Change in patient reported outcome measures before and after treatment | Six different patient reported outcome measures assessed by numerical rating scale (NRS; min-max 0-10): cough, sputum, air hunger, breathing effort, tightness in chest, anxiousness. The patients will assess symptoms prior to and after treatment | change before versus after 20 min treatment followed by 10 min rest | |
Secondary | Admission to hospital (yes/no) | Admission to hospital within or after a maximal treatment time of 1 hour | 1 hour | |
Secondary | Total treatment time | Total treatment time until oxygen saturation =96% is reached | 1 hour |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Completed |
NCT04908397 -
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
|
Phase 1 | |
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Completed |
NCT03682354 -
ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery
|
N/A | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Terminated |
NCT00233207 -
IC14 Antibodies to Treat Individuals With Acute Lung Injury
|
Phase 2 | |
Completed |
NCT00269256 -
Stress, Environment, and Genetics in Urban Children With Asthma
|
N/A | |
Completed |
NCT00281216 -
Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations
|
N/A | |
Recruiting |
NCT00129350 -
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|
Phase 1 | |
Active, not recruiting |
NCT00115297 -
Montelukast for Early Life Wheezing
|
Phase 2/Phase 3 | |
Completed |
NCT00094276 -
Intervention for Improving Asthma Care for Minority Children in Head Start
|
N/A | |
Completed |
NCT00091767 -
Genetic Studies in Difficult to Treat Asthma: TENOR
|
N/A | |
Completed |
NCT00233168 -
Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents
|
N/A | |
Completed |
NCT00069823 -
Study of Acid Reflux in Asthma
|
Phase 3 | |
Completed |
NCT00089752 -
Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea
|
N/A |